Target Price | $88.15 |
Price | $72.93 |
Potential |
20.87%
register free of charge
|
Number of Estimates | 34 |
34 Analysts have issued a price target Edwards Lifesciences 2026 .
The average Edwards Lifesciences target price is $88.15.
This is
20.87%
register free of charge
$106.05
45.41%
register free of charge
$72.72
0.29%
register free of charge
|
|
A rating was issued by 43 analysts: 27 Analysts recommend Edwards Lifesciences to buy, 15 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Edwards Lifesciences stock has an average upside potential 2026 of
20.87%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 5.44 | 6.16 |
8.57% | 13.23% | |
EBITDA Margin | 30.06% | 29.81% |
9.12% | 0.84% | |
Net Margin | 76.75% | 24.57% |
174.17% | 67.99% |
38 Analysts have issued a sales forecast Edwards Lifesciences 2025 . The average Edwards Lifesciences sales estimate is
This results in the following potential growth metrics:
28 Analysts have issued an Edwards Lifesciences EBITDA forecast 2025. The average Edwards Lifesciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
38 Edwards Lifesciences Analysts have issued a net profit forecast 2025. The average Edwards Lifesciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 6.96 | 2.57 |
202.61% | 63.07% | |
P/E | 28.50 | |
EV/Sales | 6.43 |
38 Analysts have issued a Edwards Lifesciences forecast for earnings per share. The average Edwards Lifesciences EPS is
This results in the following potential growth metrics and future valuations:
Edwards Lifesciences...
Analyst | Rating | Action | Date |
---|---|---|---|
Oppenheimer |
Locked
➜
Locked
|
Locked | Oct 08 2025 |
Evercore ISI Group |
Locked
➜
Locked
|
Locked | Oct 07 2025 |
Stifel |
Locked
➜
Locked
|
Locked | Sep 22 2025 |
Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Jul 25 2025 |
Deutsche Bank |
Locked
➜
Locked
|
Locked | Jul 25 2025 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jul 25 2025 |
Analyst Rating | Date |
---|---|
Locked
Oppenheimer:
Locked
➜
Locked
|
Oct 08 2025 |
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Oct 07 2025 |
Locked
Stifel:
Locked
➜
Locked
|
Sep 22 2025 |
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 07 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Jul 25 2025 |
Locked
Deutsche Bank:
Locked
➜
Locked
|
Jul 25 2025 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jul 25 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.